JNCE

Jounce Therapeutics, Inc. Common Stock
JNCE

Overview Fund Activity
Delisted

JNCE was delisted on the 3rd of May, 2023.

Back to rankings

72 hedge funds and large institutions have $195M invested in Jounce Therapeutics, Inc. Common Stock in 2017 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 27 increasing their positions, 16 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
72
Holders Change
+14
Holders Change %
+24.14%
% of All Funds
1.8%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.07%
New
23
Increased
27
Reduced
16
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Wellington Management Group
1
Wellington Management Group
Massachusetts
$34.2M
2
PHS
2
PFM Health Sciences
California
$9.8M
3
Acadian Asset Management
3
Acadian Asset Management
Massachusetts
$2.36M
4
Vanguard Group
4
Vanguard Group
Pennsylvania
$3.58M
5
FI
5
Fosun International
China
$1.46M

Top Sellers

1
EC
1
EcoR1 Capital
California
$0
2
DM
2
Deerfield Management
New York
$3.48M
3
Tudor Investment Corp
3
Tudor Investment Corp
Connecticut
$0
4
FCMI
4
Foresite Capital Management III
California
$0
5
Millennium Management
5
Millennium Management
New York
$2.87M
Name Holding Trade Value Shares
Change 		Shares
Change %
LCM
76
Laurion Capital Management
New York
– -$880K -40,000 Closed
HSBC Holdings
77
HSBC Holdings
United Kingdom
– -$256K -11,620 Closed
PP
78
Paloma Partners
Connecticut
– -$212K -9,612 Closed
TRCT
79
Tower Research Capital (TRC)
New York
– -$74K -3,357 Closed
UBS Group
80
UBS Group
Switzerland
– -$24K -1,110 Closed
FMA
81
FNY Managed Accounts
New York
– -$9K -440 Closed
1 2 3
4